Objective: Current published data regarding the prognostic value of microvascular invasion (MVI) in patients with prostate cancer (PCa) have yielded mixed results. Furthermore, most important series had surgical procedures performed by multiple surgeons and surgical specimens analyzed by multiple pathologists. We determined the relation of MVI with other pathologic features and whether this finding can be used as an independent prognostic factor in patients with PCa.
INTRODUCTION
Despite surgical treatment, almost 30% of the patients presenting clinically localized prostate cancer (PCa) will develop elevation of serum prostate specific antigen (PSA) in a 10 years follow up period (1) . For this reason, one of the most important challenges for urologists is the identification of patients with a high risk of disease progression that may benefit from adjuvant therapies.
To date, histological characteristics of PCa in radical prostatectomy (RP) specimens as pathological stage, final Gleason score, seminal vesicle involvement, surgical margin status, level of extraprostatic extension and tumor volume are frequently used to predict progression after surgery (2) . According to recommendations of the College of American Pathologists Cancer Committee since 1994, microvascular invasion (MVI) is reported in RP specimens (3) , even though mixed results regarding its incidence and prognostic significance are reported in literature.
Incidence rates of MVI in RP specimens range from 5 to 53% (4) (5) (6) (7) (8) (9) (10) . While many studies have found that MVI is a significant predictor of disease progression only in univariate analysis (4, 10) , others have reported its independent significance in multivariate analysis (8, 9, 11) . Furthermore, the most important series had surgical procedures performed by multiple surgeons and surgical specimens analyzed by multiple pathologists, leading to possible interpretation biases.
In the present study, the authors sought to determine the prognostic significance of MVI in predicting biochemical recurrence after surgery in a group of patients with PCa treated with RP performed by a single surgeon and with surgical specimens analyzed by a single pathologist, enhancing the uniformity of MVI assessment and other pathologic variables.
MATERIALS AND METHODS
From August 1993 to November 2000, we selected 428 patients with PCa treated with RRP. Patients with insufficient clinical data or that had undergone neoadjuvant or adjuvant treatments were excluded from the study. All cases had clinically organ confined disease suspected by high serum PSA or palpable nodule at digital rectal examination and were diagnosed by transrectal ultrasound-guided needle biopsy. Surgical procedures were performed only by one surgeon (MS) and the pathology samples analyzed by only one pathologist (KRL). Staging evaluation consisted of history, physical examination, serum PSA, MVI, computed tomography, bone scan and TUNB. The clinical staging was determined using the 1992 AJCC staging system (12) . Tumor grading was assessed according to the Gleason system (13) .
The specimens of RP were submitted to histological study in accordance with the previously described recommendations (14) . Thin transversal sections were performed in the surgical margins related to the bladder neck and the prostate apex. Seminal vesicles were sectioned in the base and longitudinal sections were submitted to histological examination. The entire gland was included for study after having their margins painted with India ink. Sequential transversal sections were performed every 3 mm, designed from the proximal region towards the distal one. Approximately 10 or 12 sections from each lobe were included for histological study. The lymph nodes from the fat related to the resection of the iliac chain were dissected and included for study. The specimens of RP underwent the usual processing with inclusion in paraffin. MVI was defined as the presence of tumor cells within an endothelium lined spaces.
Mean patient age at diagnosis was 62.8 years (range 40 to 83), and mean PSA was 10.0 ng/mL. Three hundred and thirty five (78.2%) of the 428 patients presented Gleason score of six or less, and about 50% had non-palpable disease (T1c). The mean percent positive biopsy cores (PPBC) was 41% (range 5 to 100%). After pathological examination, 72.1% of the patients showed organ confined disease (T2) and no patient showed lymph node involvement.
Patients were examined at month 2 postoperatively, and then every 6 months for 5 years and annually thereafter. At every follow up, digital rectal examination was performed and serum PSA measured. Disease recurrence was defined as a serum PSA of 0. 4 In logistic regression analysis to determine the risk of MVI at surgical specimen, we found that Mean follow-up after surgery was 53.9 ± 20.1 months. Of the 428 patients, 98 (23%) presented disease recurrence, six (1.4%) developed clinical metastasis, and no one died of PCa. Using the log rank test, we found that patients with MVI had a 44.6% probability of disease recurrence vs. 20.2% among patients without MVI (p < 0.001) (Figure-1) .
On univariate Cox proportional hazards regression analysis, all clinical and pathological characteristics but patient age and biopsy Gleason score were significantly associated with an increased risk of biochemical progression after surgery (Table-3 ). However, on multivariate analysis, only serum PSA, clinical stage, capsular involvement, surgical margin status and the presence of MVI were significantly associated with biochemical recurrence (Table-4) .
COMMENTS
In the present study, we found MVI in 11% of the 428 patients. This finding is similar to other reported series (9) . However, discrepant rates have also been reported, and this fact is probably caused by different criteria in defining MVI, interobserver interpretation, specimen handling, and by patient selection. McNeal & Yemoto (6), analyzing a similar group of patients with clinically localized disease found a 14% incidence rate, Herman (8) , studying only patients with T3 tumors found a 35% rate, and Salomao et al. (5) , found an overall incidence of 53%. The lower incidence observed in our study could be explained by a selection bias since more than 70% of patients had organ confined disease and no one showed lymph node involvement. However, as surgical specimens were analyzed by a single pathologist, the uniformity of MVI assessment and Regarding biochemical recurrence after RP, our study also supports MVI as an independent prognostic variable. This finding was reproduced by other authors. McNeal and Yemoto (6), analyzing 357 radical prostatectomy specimens, found that the only independent predictors of biochemical recurrence were MVI, carcinoma grade, and cancer volume. de la Taille (9), analyzing 241 patients, found that biochemical recurrence-free survival was 92.5% for the patients without MVI as compared to 30.1% for patients with MVI on prostate specimen examination.
MVI, preoperative PSA and pathological stage were independent prognostic variables of biochemical recurrence. Likewise, Ito et al. (11) , found that MVI along with Gleason grade and capsular penetration, were disease recurrence independent prognostic factors. Herman et al. (8) , found a significant correlation between MVI and increasing tumor volume, increasing Gleason grade, level of extraprostatic extension and the presence of seminal vesicle involvement. At 5 years, 45% and 21% of patients with and without MVI respectively presented disease progression. In multivariate analysis, MVI showed independent significance in predicting disease progression. More recently, Ferrari et al. (15) , found a significant correlation with high Gleason grade, extracapsular extension, seminal vesicle invasion, increasing cancer volumes, positive margins, and elevated preoperative PSA levels. MVI was a strong and independent predictor for disease recurrence, however, in contrast to our study, the surgical procedures in this series were performed by several surgeons and it is possible that different surgical techniques have affected outcomes in the study group.
Conversely, to these reports, Bahnson et al. (4), described that despite the association of MVI with a fourfold greater incidence of progression and or death, in multivariate analysis, its prognostic significance was dependent upon tumor grade. More recently, Shariat et al. (10) , confirmed the association of MVI with features of biologically aggressive PCa and found a strong association between MVI and metastasis to regional lymph nodes. These findings suggest that MVI precedes or occurs coincidently with lymph node metastasis, however MVI was not an independent prognostic factor for biochemical recurrence on multivariate analysis. These results could be attributed to the short follow up period (median 21 months). Again, multiple surgeons and pathologists were involved in this report, contributing to possible interpretation biases.
Some limitations in this study should be considered. Since no patient presented lymph node involvement, this variable could not be related to MVI or used in multivariate analysis. Furthermore, despite our mean 53.9 months follow-up being longer than most previous studies analyzing MVI, the number of patients who developed clinical metastasis was limited (only six), and no one died of PCa. This fact limits the power of our study to analyze associations between these outcomes and MVI. Finally, the number of MVI foci was not quantified on surgical specimens, and this information could have provided additional prognostic information since the finding of more than five foci seems to connote a dire prognosis (15) .
In conclusion, with the present study, we support MVI as an important pathologic feature in a group of patients with PCa treated by the same surgeon and with pathological analysis performed by a single pathologist. After the follow-up period, 44.6% vs. 20.2% of the patients with and without MVI had biochemical recurrence respectively. Additionally, MVI along with serum PSA, clinical stage, capsular involvement and surgical margin status were independent predictors for recurrence when controlled for the other variables. This variable should be routinely used to help selection of patients to adjuvant treatments.
prostatectomies performed by a single surgeon with a mean follow-up of 53 months. The pathology was read by a single pathologist, and although this can be considered a strong point, the question of variability of the MVD readings was not addressed in this paper. Of all the cases examined, only 11% were found to have MVI. What if there were several pathologists reviewing this blindly. Would that 11% be consistent?
The significant findings of this paper were that MVI had a 44.6% probability of disease recurrence vs. 20.2% among patients without MVI (p < 0.001). Unfortunately, there was no data presented in the paper indicating whether or not these biochemical recurrences were early or late when compared to the patients that did not have MVI. In addition, in an era when PSA doubling time has become an important surrogate prognostic indicator of metastatic disease and survival, there should have been some mention of this indicator. This type of information may have been meaningful, and should be explored, especially since there were only 6 patients that developed metastatic disease in the study and there were no prostate cancer deaths. Interestingly, there was a lack of association with biopsy Gleason score, which has been determined by previous authors. So, are these findings meaningful, and will they change the patterns of care of our patients? Should this be done routinely, as the authors suggest, and discussed with patients in the postoperative consultation? "Sir, your have MVI, so, we now recommend…??" Clearly, this needs more validation before we can use this to base adjuvant treatment decisions. I believe that we should be ordering tests only if we are going to act on the outcome. Otherwise, it is a research tool, and what is truly needed to answer this question is a randomized trial, which would demonstrate that adjuvant therapy in patients with MVI will improve the outcome, or have one as good as the MVI negative patients. Until then, its still research, and I commend the authors for trying to determine the true significance of this pathological finding (artifact?). 
Dr. Aaron Edward Katz

EDITORIAL COMMENT
The importance of microvascular invasion (MVI) on prognostic information in urological malignancy is fully evaluated in the recent years (1, 2) . This paper presented the prognostic significance of MVI for biochemical recurrence after radical prostatectomy in 428 patients with prostate cancer. As the data were collected by a single surgeon and examined by a single pathologist, the analysis is consistent and reasonable. Multivariate analysis demonstrated that 5 factors including serum PSA, clinical stage, capsular involvement, surgical margin status, and the presence of MVI were significant predictors for biochemical recurrence. As would be expected, the importance of MVI on prognostic impact for biochemical recurrence is not so high that other factors such as PSA and capsular involvement were still strong in this study population. For a given PSA value and/or presence or absence of capsular involvement, how can MVI add prognostic information to these already known poor prognostic factors? The re-evaluation for the importance of MVI in more homogenous subpopulation might be more informative. Furthermore, in a clinical point of view, risk stratification or nomogram to identify the patients who should receive adjuvant therapy would need to be created. We still have an effort to confirm the importance of MVI for prognostic information for prostate cancer in a large, randomized, prospective study.
